CELL INTELLIGENCE · 肿瘤细胞治疗研究

反应性十二指肠活检中可检测到高度偏斜的 T 细胞受体免疫组化 αβ:γδ 比值：T 细胞淋巴瘤诊断中的潜在陷阱

Highly Skewed Immunohistochemical αβ:γδ Ratios for T-Cell Receptors Can Be Detected in Reactive Duodenal Biopsies: A Potential Pitfall in the Diagnosi

靶向 CCR5 的同种异体 γδ CD19 CAR-T 细胞用于 HIV 相关 B 细胞恶性肿瘤免疫治疗

CCR5-targeted allogeneic gamma-delta CD19 chimeric antigen receptor T cells for HIV-associated B cell-malignancy immunotherapy.

新型异基因利妥昔单抗偶联 γδ T 细胞疗法治疗复发/难治性 B 细胞淋巴瘤

A Novel Allogeneic Rituximab-Conjugated Gamma Delta T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Lymphoma.

单倍体相合γδ T 细胞诱导化疗难治性 B 细胞非霍奇金淋巴瘤完全缓解

Haploidentical γδ T Cells Induce Complete Remission in Chemorefractory B-cell Non-Hodgkin Lymphoma.

HLA 全不合同胞来源 CD7 CAR-T 治疗桥接单倍体造血干细胞移植治疗肝脾 γδ T 细胞淋巴瘤

HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell

用于肿瘤免疫治疗的 CAR γδ T 细胞：该领域是否黄多于绿

CAR γδ T cells for cancer immunotherapy. Is the field more yellow than green?

定制 CAR：利用异体 CAR 疗法的适应性应对复发/难治性 DLBCL 的当前挑战

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.

异体 CD20 靶向 γδ T 细胞在临床前 B 细胞淋巴瘤模型中展现固有与适应性抗肿瘤活性

Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models.

这些临床前数据支持 ADI-001（一种同种异体 CD20 CAR⁺ Vδ1 T 细胞）的临床评价，一项 1 期研究已在 B 细胞恶性肿瘤患者中启动（NCT04735471）。